Newsletter Tool

Drug Delivery

This Week

Feb 1, 2023

Following in Lilly's footsteps, Teva takes 2nd long-acting schizophrenia drug into phase 3

FDA extends review of argenx's subcutaneous efgartigimod, pushing decision date back into June

Waste not, want not: Aptar creates metal-free nasal spray pump to boost recyclability

Seeking improved efficacy, Sensorion taps Eveon to deliver gene therapy to inner ear

Featured

Following in Lilly's footsteps, Teva takes 2nd long-acting schizophrenia drug into phase 3

By Nick Paul Taylor

Teva Pharmaceutical has opened another front in its expansion into long-acting injectables, kicking off a phase 3 clinical trial of a prospect based on the same technology as its near-approval schizophrenia drug.

FDA extends review of argenx's subcutaneous efgartigimod, pushing decision date back into June

By Nick Paul Taylor

The FDA is making argenx wait on an approval decision for subcutaneous efgartigimod. After receiving more information from argenx, the regulator extended the review and pushed the PDUFA date back to the summer.

Waste not, want not: Aptar creates metal-free nasal spray pump to boost recyclability

By Nick Paul Taylor

Aptar Pharma wants to reduce the waste generated by your nasal spray pumps. With the launch of APF Futurity, the drug delivery specialist has made a metal-free, multi-dose nasal spray pump available to meet demand for recyclable products.

Seeking improved efficacy, Sensorion taps Eveon to deliver gene therapy to inner ear

By Nick Paul Taylor

Sensorion has partnered to improve the delivery of its hearing loss gene therapy OTOF-GT. Working with Eveon, the French biotech is aiming to develop an injection system for getting its therapies to the inner ear.

The top 10 biopharma M&A deals of 2022

By Eric Sagonowsky,Kevin Dunleavy,Fraiser Kansteiner,Angus Liu,Zoey Becker

Heading into 2022, top drugmakers had $1.7 trillion in dealmaking firepower, fueling expectations among analysts that the industry was due for a gangbusters M&A year. Well, that didn’t quite pan out.

10 top M&A targets in biotech for 2023

By James Waldron,Annalee Armstrong,Nick Paul Taylor

After a slow 2022, will we see a return to form for biopharma M&A? And, if so, which biotechs does Big Pharma have in its sight? Here are our predictions.

Fierce podcasts

Don't miss an episode

'The Top Line': Inflation Reduction Act, and biotech's outlook

This week on "The Top Line," we hear from Stacie Dusetzina, Ph.D., a professor at Vanderbilt University's Department of Health Policy, about what the IRA means for the pharma industry. We'll also discuss what we can expect from the biotech industry in 2023.